ViiV / Gilead
ViiV Publikationen vom CROI Kongress 2026
|
CABOTEGRAVIR + RILPIVIRINE Long-acting for treatment |
|
|
Body Mass Index and Virologic Outcomes in Individuals on CAB+RPV LA in the OPERA Cohort Michael G. Sension et al. - Poster |
|
|
Early Switch to CAB+RPV LA in Treatment-Naive Adults With HIV-1: Month 11 Outcomes From VOLITION Charlotte-Paige Rolle et al. - Poster |
|
|
HIV-HBV Coinfection and Long-Acting Cabotegravir + Rilpivirine in the US: HBV and HIV Outcomes Douglas T Dieterich et al. - Poster/ Poster Walk |
|
|
Outcomes for Individuals who Initiate CAB+RPV LA in OPERA with Viral Loads ≥50 vs. <50 copies/mL Ricky K. Hsu et al. - Poster |
|
|
DOLUTEGRAVIR-based regimens |
|
|
CD4/CD8 T Cell Telomere Length at 96 Weeks in the PASO-DOBLE Trial Comparing BIC/FTC/TAF and DTG/3TC* Andrés Esteban-Cantos et al. - Poster |
|
|
Effect of DTG/3TC vs. BIC/FTC/TAF on Steatotic Liver Disease: 96-week Analysis of PASO-DOBLE Trial* Juan A Pineda et al. - Themed Discussion & Poster |
|
|
Efficacy and safety of switching to DTG/3TC dual therapy from B/F/TAF among older adults ≥60 years* Loice Achieng Ombajo et al. - Poster |
|
|
Transcriptomic Changes in Adipose Tissue of People with HIV on BIC/FTC/TAF or DTG/3TC Treatment* Domingo, Pere et al. - Poster |
|
|
Evaluating the impact of integrase inhibitors (INSTIs) on cardiovascular disease (CVD) Bernard Surial et al. - Poster |
|
|
Meta-analysis of DTG/3TC vs DTG 3DRs In ART-Naïve People with High Baseline Viral Loads and Low CD4+ Pedro Cahn et al. - Poster |
|
|
Viral Suppression with Dolutegravir-Based Regimens in Children ≤5 Years Old in Southern Africa Kim Anderson et al. - Poster |
|
|
Pipeline |
|
|
Dose Selection of Ultra-Long-Acting Cabotegravir as HIV-1 Pre-Exposure Prophylaxis: A Phase 1 Study Eileen Castronova et al. - Poster |
|
|
Injectable HIV-1 Capsid Inhibitor VH4011499 (VH-499) Formulation Supports Ultra-Long-Acting Dosing Nilay Thakkar et al. - Oral Presentation |
|
|
Maintenance of HIV Suppression at 12 Months With VH3810109 (N6LS) Q4M + CAB LA QM: The EMBRACE Study Charlotte-Paige Rolle et al. - Oral Presentation |
|
|
Pharmacokinetics and Evaluation of Potential Dosing Regimens for Long-Acting VH4524184 Hyunmoon Back et al. - Oral Presentation |
|
|
Population PK and Exposure-Response Analysis of Orally Administered VH4011499 in people living with HIV-1 Nilay Thakkar et al. - Poster |
|
|
Third-Generation INSTI VH4524184 (VH-184) Has an Enhanced Resistance Profile vs Bictegravir Mark Underwood et al. - Poster |
|
*denotes ViiV-supported investigator led and collaborative studies
Gilead-initiated or Gilead-supported Abstracts Published at CROI 2026
|
B/F/TAF |
||
|
Oral / Poster |
1st Author |
Title |
|
Poster 852 |
Natukunda, E |
Efficacy and Safety of B/F/TAF in Children and Infants Aged ≥1 Month, Weighing 3 to <25 kg: Week 24 |
|
BIC/LEN |
||
|
Oral / Poster |
1st Author |
Title |
|
Oral 181 |
Orkin, CM |
Phase 3 Efficacy and Safety of Switch from Complex Regimen to Single-Tablet BIC/LEN in ARTISTRY-1 |
|
Poster 513 |
Meissner, E |
Phase 3 Efficacy and Safety of Switch from B/F/TAF to Single-Tablet BIC/LEN in ARTISTRY-2 |
|
Poster 518 |
Hedgcock,M |
Switch to BIC+LEN in VS PWH on Complex Regimens: Week 96 Outcomes |
|
ISL/LEN |
||
|
Oral / Poster |
1st Author |
Title |
|
Poster 516 |
Colson, AE |
Once-Weekly Islatravir Plus Lenacapavir Maintains HIV-1 Suppression Through 96 Weeks: Phase 2 Study |
|
Poster 586 |
Bekerman, E |
Resistance Analysis of Weekly Islatravir Plus Lenacapavir in People with HIV-1 at 96 Weeks |
|
LEN+TAB+ZAB |
||
|
Oral / Poster |
1st Author |
Title |
|
Poster 567 |
VanderVeen, L |
Twice-Yearly Lenacapavir, Teropavimab, and Zinlirvimab for HIV-1: Week 52 Resistance Analyses |
|
Poster 517 |
Gaur, A |
Patient-Reported Outcomes after 52 Weeks of Twice-Yearly Lenacapavir, Teropavimab, and Zinlirvimab |
|
GS-3242 (LA INSTI) |
||
|
Oral / Poster |
1st Author |
Title |
|
Oral 174 |
Gupta, S |
Safety, Pharmacokinetics, and Antiviral Activity of GS-3242, a Novel Long-Acting Injectable INSTI |
|
Poster 521 |
Hansen, D |
Nonclinical Pharmacology of GS-3242, a Novel Long-Acting Injectable INSTI in Clinica Development |
|
Poster 490 |
Subramanian, M |
Nonclinical Pharmacokinetics of a Novel INSTI GS-3242 supports a Human Long-Acting Injectable |
|
LEN FOR HTE PWH |
||
|
Oral / Poster |
1st Author |
Title |
|
Poster 539 |
Ogbuagu, O |
Long-term Effectiveness of Lenacapavir in Heavily Treatment-Experienced People with HIV-1 in the US |
|
Poster 581 |
Margot, N |
HIV-1 Susceptibility to Lenacapavir is Not Affected by Capsid Protein Polymorphisms T107A and T107S |
|
HIV PREVENTION |
||
|
Oral / Poster |
1st Author |
Title |
|
Oral 130 |
Cox, S |
Resistance Analysis of the PURPOSE StudiesThrough the End of the Randomized Blinded Phase |
|
Oral 129 |
Cantos, VD |
Lenacapavir for PrEP: HIV-1 Incidence and Safety from PURPOSE 2 at End of Randomized Blinded Phase |
|
Oral 128 |
Ndlovu, N |
Twice-yearly Subcutaneous Lenacapavir for PrEP: Updated HIV-1 Incidence and Safety Data in PURPOSE 1 |
|
Poster 996 |
Hughes, E |
Once-yearly Lenacapavir for PrEP: Model-Informed Dose Determination and Phase 3 Trial Design |
|
Poster 1062 |
Tao, L |
Real-World Use: Potential Medication Interactions with Lenacapavir for HIV preexposure prophylaxis |
|
Poster 1087 |
Moore, M |
Expected impact of twice-yearly lenacapavir on PrEP coverage disparities and HIV incidence in the US |
|
Poster 1090 |
Gursel, E |
Removing Insurance Barriers to Oral PrEP Access Reduces HIV Cases and Costs in Key US Populations |
|
HIV CURE |
||
|
Oral / Poster |
1st Author |
Title |
|
Poster 371 |
Workowski, K |
Safety, PK, and Pharmacodynamics of Amtabafusp, a Bispecific T-cell Engager, in People with HIV |
|
Oral 137 |
Murry, JP |
CD4-Targeted IL-15 Enhanced bNAb Activity and Improved SHIV Control After Treatment Interruption |
|
Poster 289 |
Sharma, B |
Conserved HIV Immunogen Broadens T-Cell Immunity and Enhances CD8+ Antiviral Activity |
|
Poster 574 |
Selzer, L |
BNAb sensitivity does not fully explain posttreatment control in early HIV-treated women during ATI |
|
Poster 584 |
Irwan, I |
Mechanisms of HIV-Infected Cell Persistence Following Exposure to HIV Protease Activators |
|
Poster 423 |
Gumede, N |
|
|
HDV |
||
|
Oral / Poster |
1st Author |
Title |
|
Oral 141 |
Wyles, D |
Efficacy and Safety of BLV 2 or 10 mg in CHD Including Patients With HIV/HBV: MYR301 Final Results |
Selected Gilead-supported abstracts
|
B/F/TAF |
||
|
Oral / Poster |
1st Author |
Title |
|
Poster 851 |
Kamphuis, AEM |
Pharmacokinetics of an Optimized dose Ratio of DTG/FTC/TAF for Children with HIV: UNIVERSAL1 Study |
|
Poster 687 |
Bourgi, K |
NNRTI-to-INSTI Switches Across North America May Have Had a Substantial Population Impact on Weight |
|
Poster 686 |
Perez-Valero, I |
Metabolic Effects of Switching From DTG/3TC to B/F/TAF in PWH with Neuropsychiatric Conditions |
|
LEN for THE PWH |
||
|
Oral / Poster |
1st Author |
Title |
|
Poster 540 |
Palich, R |
Real world use of lenacapavir in France: a national, observational study |
Diese Seite weiter empfehlen